329 related articles for article (PubMed ID: 26028398)
61. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
Chirakup S; Chaiyakunapruk N; Chaikledkeaw U; Pongcharoensuk P; Ongphiphadhanakul B; Roze S; Valentine WJ; Palmer AJ
Value Health; 2008 Mar; 11 Suppl 1():S43-51. PubMed ID: 18387067
[TBL] [Abstract][Full Text] [Related]
62. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
Paneni F; Lüscher TF
Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
[TBL] [Abstract][Full Text] [Related]
63. New insights into the older hypoglycemic agents in type 2 diabetes therapy.
Cao M; Bloomgarden Z
J Diabetes; 2020 Nov; 12(11):844-847. PubMed ID: 32767624
[No Abstract] [Full Text] [Related]
64. Which oral drug is right for your type 2 diabetes? New thinking on oral drug combinations that can provide better glycemic control.
Health News; 2005 Feb; 11(2):10-1. PubMed ID: 15732153
[No Abstract] [Full Text] [Related]
65. Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: impact on cardiovascular events. A randomized controlled trial.
Vaccaro O; Masulli M; Bonora E; Del Prato S; Giorda CB; Maggioni AP; Mocarelli P; Nicolucci A; Rivellese AA; Squatrito S; Riccardi G;
Nutr Metab Cardiovasc Dis; 2012 Nov; 22(11):997-1006. PubMed ID: 23063367
[TBL] [Abstract][Full Text] [Related]
66. [Newer anti - diabetic therapies and chronic kidney disease].
Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
[TBL] [Abstract][Full Text] [Related]
67. Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.
Frandsen CS; Dejgaard TF; Madsbad S
Lancet Diabetes Endocrinol; 2016 Sep; 4(9):766-780. PubMed ID: 26969516
[TBL] [Abstract][Full Text] [Related]
68. Oral pharmacologic management of type 2 diabetes.
Riddle MC
Am Fam Physician; 1999 Dec; 60(9):2613-20. PubMed ID: 10605995
[TBL] [Abstract][Full Text] [Related]
69. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
Gamble JM; Donnan JR; Chibrikov E; Twells LK; Midodzi WK; Majumdar SR
Sci Rep; 2018 Oct; 8(1):15142. PubMed ID: 30310100
[TBL] [Abstract][Full Text] [Related]
70. [Gliptin-gliflozin combination for treating type 2 diabetes].
Scheen AJ; Paquot N
Rev Med Suisse; 2016 Aug; 12(527):1384-1388. PubMed ID: 28671793
[TBL] [Abstract][Full Text] [Related]
71. Type 2 diabetes management: a comprehensive clinical review of oral medications.
Quillen DM; Kuritzky L
Compr Ther; 2002; 28(1):50-61. PubMed ID: 11894443
[TBL] [Abstract][Full Text] [Related]
72. Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy.
Gilbert RE; Krum H
Lancet; 2015 May; 385(9982):2107-17. PubMed ID: 26009231
[TBL] [Abstract][Full Text] [Related]
73. A decision support tool for appropriate glucose-lowering therapy in patients with type 2 diabetes.
Ampudia-Blasco FJ; Benhamou PY; Charpentier G; Consoli A; Diamant M; Gallwitz B; Khunti K; Mathieu C; Ridderstråle M; Seufert J; Tack C; Vilsbøll T; Phan TM; Stoevelaar H
Diabetes Technol Ther; 2015 Mar; 17(3):194-202. PubMed ID: 25347226
[TBL] [Abstract][Full Text] [Related]
74. The prescribing trend of oral antidiabetic agents for type 2 diabetes in Taiwan: An 8-year population-based study.
Chu WM; Ho HE; Huang KH; Tsan YT; Liou YS; Wang YH; Lee MC; Li YC
Medicine (Baltimore); 2017 Oct; 96(43):e8257. PubMed ID: 29068991
[TBL] [Abstract][Full Text] [Related]
75. Use of non-insulin therapies for type 1 diabetes.
Garg SK; Michels AW; Shah VN
Diabetes Technol Ther; 2013 Nov; 15(11):901-8. PubMed ID: 24131372
[No Abstract] [Full Text] [Related]
76. Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence.
Liu Y; Hong T
Diabetes Obes Metab; 2014 Feb; 16(2):111-7. PubMed ID: 23668534
[TBL] [Abstract][Full Text] [Related]
77. A 5-year trend in the use of sodium-glucose co-transporter 2 inhibitors and other oral antidiabetic drugs in a Middle Eastern country.
Zaghloul N; Awaisu A; Mahfouz A; Alyafei S; Elewa H
Int J Clin Pharm; 2022 Dec; 44(6):1342-1350. PubMed ID: 36169802
[TBL] [Abstract][Full Text] [Related]
78. Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet.
Bachmann KN; Roumie CL; Wiese AD; Grijalva CG; Buse JB; Bradford R; Zalimeni EO; Knoepp P; Dard S; Morris HL; Donahoo WT; Fanous N; Fonseca V; Katalenich B; Choi S; Louzao D; O'Brien E; Cook MM; Rothman RL; Chakkalakal RJ
Pharmacol Res Perspect; 2020 Oct; 8(5):e00637. PubMed ID: 32881317
[TBL] [Abstract][Full Text] [Related]
79. [The safety of anti-diabetic drugs in heart failure].
Frigy A; Germán-Salló M; Máthé L; Szabó M
Orv Hetil; 2017 Feb; 158(5):163-171. PubMed ID: 28132538
[TBL] [Abstract][Full Text] [Related]
80. Oral combination therapy for type 2 diabetes.
Charpentier G
Diabetes Metab Res Rev; 2002; 18 Suppl 3():S70-6. PubMed ID: 12324989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
